摘要
目的检测肾细胞癌(renal cell carcinoma,RCC)中核糖体S6蛋白激酶4(RSK4)的表达,探讨其表达水平与肿瘤临床病理特征及预后的相关性。方法采用免疫组化EnVision两步法检测70例RCC标本中RSK4蛋白的表达,并应用统计学方法分析RSK4表达与患者临床病理特征及预后的相关性。结果 70例RCC标本中,39例为RSK4阳性表达,且不同病理类型的RSK4阳性表达水平不一。经统计学分析,RSK4的阳性表达与肿瘤的高Fuhrman分级(P<0.001)、高病理分期(P=0.006)及出现淋巴结转移(P=0.012)呈正相关;行单因素及多因素生存分析显示,RSK4阳性表达与RCC患者不良预后相关(P=0.001)。结论 RSK4有助于不同类型RCC的鉴别诊断及其可以成为RCC的潜在的独立预后因子之一。
Purpose To investigate the expression of RSK4 protein in renal cell carcinoma （RCC） and to explore its association with the clinicopathologic features and clinical outcome. Methods The expression of RSK4 was detected by immunohistochemistry and its relationship with clinicopathologic features and prognosis were analyzed by statistical methods. Results Thirty-nine out of seventy RCC cases were positive for RSK4, and the positivity varied in different pathological subtype. Further statistical analysis showed that the expression of RSK4 was positively correlated with higher Fuhrman grading （P 〈 0. 001 ） , pT staging （P = 0. 006 ） and lymphonode involvement （P = 0. 012）. Uni- and muhi-variate survival analysis showed the positive expression of RSK4 predicted a poor survival（ P = 0. 001 ） in all RCC patients. Conclusions The expression of RSK4 could be helpful for the differential diagnosis of RCC subtypes and be a potential independent prognostic predictor for RCC.
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2013年第2期141-146,共6页
Chinese Journal of Clinical and Experimental Pathology
基金
国家自然科学基金青年基金(81001140)
